Cargando…
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases
Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product of (188)W/(188)Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9 h and a maximal β-energy of 2.1 MeV. We investigated...
Autores principales: | Liepe, K, Kropp, J, Runge, R, Kotzerke, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376909/ https://www.ncbi.nlm.nih.gov/pubmed/12915868 http://dx.doi.org/10.1038/sj.bjc.6601158 |
Ejemplares similares
-
(188)Re-HEDP therapy in the therapy of painful bone metastases
por: Liepe, Knut
Publicado: (2018) -
Rhenium-188 Hydroxyethane 1,1-Diphosphonic Acid (HEDP) for Bone Pain Palliation Using BARC-HEDP Kits versus Pars-HEDP Kits: A Comparison on Preparation and Performance Aspects at Hospital Radiopharmacy
por: Ramakurup, Radhakrishnan Edathuruthy Kalarickal, et al.
Publicado: (2018) -
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
por: O'Sullivan, J M, et al.
Publicado: (2002) -
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
por: Lam, Marnix G. E. H., et al.
Publicado: (2009) -
Rhenium 188: The Poor Man's Yttrium
por: Shinto, Ajit
Publicado: (2017)